Sigma-Tau Pharmaceuticals (United States)
- Research works
- 16 ▲ 21% vs 2018-21
- Citations
- 869 53.8 per fractional work
- Top-10% rate
- 11.8% all institutions 10.0%
- Open access
- 27% world 40%
- International
- 42% world 18%
Not ranked overall: Sigma-Tau Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.
Which fields of science does Sigma-Tau Pharmaceuticals (United States) work in?
In all years, 64% of research at Sigma-Tau Pharmaceuticals (United States) is in Health Sciences, 32% in Life Sciences. Its largest fields are Medicine (60%), Biochemistry, Genetics and Molecular Biology (25%), Pharmacology, Toxicology and Pharmaceutics (3%). It does 2.0× the world's share of Health Sciences.
Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.
Its 4 domains and 15 fields, with their numbers
- Health Sciences1063.6%
- Medicine1060.0%
- Nursing02.0%
- Health Professions01.5%
- Life Sciences531.7%
- Physical Sciences14.2%
- Environmental Science02.0%
- Chemistry00.7%
- Engineering00.6%
- Materials Science00.4%
- Mathematics00.4%
- Social Sciences00.6%
- Psychology00.2%
- Economics, Econometrics and Finance00.2%
- Social Sciences00.2%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Who are the top researchers at Sigma-Tau Pharmaceuticals (United States)?
Ranked on the quality score, Antonino Amato lead among researchers whose main affiliation is Sigma-Tau Pharmaceuticals (United States).
- 1
Antonino Amato
United States · #2,654,318 worldwide 2.9k citations · 70 works
Which research topics does Sigma-Tau Pharmaceuticals (United States) publish most on?
By volume in 2022-now: Ovarian function and disorders, Reproductive Biology and Fertility and TGF-β signaling in diseases.
Area is fractional works; colour is the subfield each topic belongs to.
How open and international is its research?
Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 40% of research is openly available.
World: 18% is written across borders.
How has Sigma-Tau Pharmaceuticals (United States)'s research output changed?
Output in 2022-2025 was 21% higher than in 2018-2021.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is Sigma-Tau Pharmaceuticals (United States) as a percentage of every work published that year, 0.0000033% in 2018.
Fractional works of Sigma-Tau Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.
Other research institutions in Gaithersburg
- National Institute of Standards and Technology
- Molecular Oncology (United States)
- Scientific Consulting Group
- Robotic Research (United States)
- GenVec
- CVPath Institute
- Identity
- Integrated BioTherapeutics (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.
Discussion
Ask a question or share a note about Sigma-Tau Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.